ABSORB II RANDOMIZED CONTROLLED TRIAL A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions.

Trial Profile

ABSORB II RANDOMIZED CONTROLLED TRIAL A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms ABSORB-II
  • Sponsors Abbott Vascular
  • Most Recent Events

    • 04 Jul 2017 Results published in the Journal of the American College of Cardiology
    • 30 Oct 2016 Primary endpoint (Angiographic late luminal loss-Minimum Lumen Diameter (MLD) post nitrate minus MLD post procedure post nitrate by QCA (non-inferiority, reflex to superiority)) has not been met.
    • 30 Oct 2016 Primary (Vasomotion assessed by change in Mean Lumen Diameter (MLD) between pre- and post-nitrate quantitative coronary angiography (QCA) (superiority)) endpoint has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top